RedHill Biopharma (RDHL) Debt to Equity (2020 - 2022)
Historic Debt to Equity for RedHill Biopharma (RDHL) over the last 3 years, with Q4 2022 value amounting to -$4.76.
- RedHill Biopharma's Debt to Equity fell 15053.07% to -$4.76 in Q4 2022 from the same period last year, while for Dec 2022 it was -$4.76, marking a year-over-year decrease of 15053.07%. This contributed to the annual value of -$4.76 for FY2022, which is 15053.07% down from last year.
- As of Q4 2022, RedHill Biopharma's Debt to Equity stood at -$4.76, which was down 15053.07% from $9.42 recorded in Q4 2021.
- RedHill Biopharma's 5-year Debt to Equity high stood at $9.42 for Q4 2021, and its period low was -$4.76 during Q4 2022.
- Its 3-year average for Debt to Equity is $3.51, with a median of $5.87 in 2020.
- In the last 5 years, RedHill Biopharma's Debt to Equity skyrocketed by 6050.21% in 2021 and then crashed by 15053.07% in 2022.
- Over the past 3 years, RedHill Biopharma's Debt to Equity (Quarter) stood at $5.87 in 2020, then surged by 60.5% to $9.42 in 2021, then tumbled by 150.53% to -$4.76 in 2022.
- Its Debt to Equity was -$4.76 in Q4 2022, compared to $9.42 in Q4 2021 and $5.87 in Q4 2020.